Risperidone-d₅is intended for use as an internal standard for the quantification of risperidone by GC- or LC-MS. Risperidone is an atypical antipsychotic that binds to dopamine D₂receptors (K_i= 3 nM) and the serotonin (5-HT) receptor subtype 5-HT_2A(K_i= 0.12 nM).^1,2It also binds to dopamine D₄, α₁- and α₂-adrenergic, 5-HT_1C, 5-HT_1D, and histamine H₁receptors (K_is = 7, 0.81, 7.3, 47, 52, and 2.1 nM, respectively). Risperidone (0.1 mg/kg per day, i.p.) attenuates deficits in prepulse inhibition of the acoustic startle response, but not deficits in social interaction, in a rat neonatal ventral hippocampal lesion model of schizophrenia.³Formulations containing risperidone have been used in the treatment of schizophrenia and bipolar disorder.

1.Leysen, J.E., Janssen, P.M., Gommeren, W., et al.In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidoneMol. Pharmacol.41(3)494-508(1992) 2.Bymaster, F.P., Calligaro, D.O., Falcone, J.F., et al.Radioreceptor binding profile of the atypical antipsychotic olanzapineNeuropsychopharmacology14(2)87-96(1996) 3.Rueter, L.E., Ballard, M.E., Gallagher, K.B., et al.Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophreniaPsychopharmacology (Berl).176(3-4)312-319(2004)